Voyager Therapeutics (NASDAQ:VYGR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday, February 2nd.
According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
A number of other research analysts also recently commented on VYGR. BidaskClub raised Voyager Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, January 26th. Morgan Stanley assumed coverage on Voyager Therapeutics in a report on Friday, February 2nd. They issued an “overweight” rating for the company. Canaccord Genuity reissued a “buy” rating and issued a $26.00 price target on shares of Voyager Therapeutics in a report on Tuesday, January 23rd. Chardan Capital reissued a “hold” rating and issued a $17.00 price target on shares of Voyager Therapeutics in a report on Tuesday, October 31st. Finally, Wedbush restated a “positive” rating and set a $31.00 price objective (down previously from $36.00) on shares of Voyager Therapeutics in a research note on Tuesday, October 31st. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $26.90.
In other news, insider Bernard Ravina sold 3,630 shares of the stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $16.40, for a total transaction of $59,532.00. Following the sale, the insider now directly owns 7,353 shares in the company, valued at approximately $120,589.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.00% of the stock is currently owned by corporate insiders.
Institutional investors have recently made changes to their positions in the company. Thompson Davis & CO. Inc. raised its position in shares of Voyager Therapeutics by 67.7% during the 4th quarter. Thompson Davis & CO. Inc. now owns 7,485 shares of the company’s stock worth $124,000 after purchasing an additional 3,021 shares during the period. JPMorgan Chase & Co. acquired a new stake in shares of Voyager Therapeutics during the 3rd quarter worth approximately $270,000. Bailard Inc. acquired a new stake in shares of Voyager Therapeutics during the 4th quarter worth approximately $232,000. Rhumbline Advisers raised its position in shares of Voyager Therapeutics by 34.7% during the 2nd quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock worth $144,000 after purchasing an additional 4,144 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in shares of Voyager Therapeutics by 8.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock worth $153,000 after purchasing an additional 1,399 shares during the period. Institutional investors and hedge funds own 36.18% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.